Navigation Links
Results of the REMEDEE trial reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 A randomized comparison of a dual therapy stent which combines low-dose sirolimus delivery from an abluminal biodegradable polymer matrix with a covalently bound anti-CD34 antibody layer with a paclitaxel-eluting stent showed that the dual therapy stent effectively controls neointimal proliferation and was shown to be safe and effective. Results of the REMEDEE trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

The REMEDEE trial was designed to demonstrate the safety and effectiveness of the new dual therapy stent compared to a clinically proven paclitaxel-eluting stent. The new stent is designed for control of neointimal proliferation as well as accelerated vessel healing. The trial was conducted among patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a single native coronary artery.

In the study, 183 patients were randomized at 17 sites in Australia (4), Belgium (2), Brazil (2), Germany (2), Hong Kong (1), Malaysia (2), Netherlands (2), and Singapore (2). Of all subjects enrolled, 124 subjects were placed in the dual therapy group and 59 in the paclitaxel-eluting group.

Major inclusion criteria included single de-novo lesions in native coronary arteries, lesion length ≤ 20 mm and a diameter of 2.5 mm to 3.5. Major exclusion criteria were acute myocardial infarction, ostial lesions and unprotected left main with ≥ 50% stenosis. Baseline patient characteristics included a mean age of 64.2 in the dual therapy group and 64.0 in the paclitaxel-eluting group; 71.8% male in the dual therapy group and 71.2% in the paclitaxel-eluting group. The mean number of lesions treated per patients was 1.1 in both groups.

The primary endpoint was angiographic in-stent late lumen loss at nine months post-procedure.

Secondary endpoints include the occurrence of death, myocardial infarction, stent thrombosis and clinically-driven revascularization reported as individual events and composites at the time of the procedure and post-procedure at 30 days, nine months, 12 months, and annually to five years.

In-stent late lumen loss at nine months for the dual therapy stent was a mean of .39 0.45 mm and .44 0.56 mm in the paclitaxel-eluting stent. At nine months, there were 1% deaths in the combo group, and 0% in the paclitaxel group. The rate of myocardial infarction at nine months was 2.4% in the combo group and 1.7% in the paclitaxel group. And, the rate of major adverse cardiac events (MACE) at nine months was 8.7% in the combo group and 11.0% in the paclitaxel group. Both groups had 0% stent thrombosis at nine months.

"In this first-in-man study, the dual therapy stent effectively controls neointimal proliferation," said lead researcher Michael Haude, MD. Dr Haude is Professor of Internal Medicine at Lukaskrankenhaus Neuss in Germany.

"There was an overall low rate of clinical events in both study groups, including no stent thrombosis. In-stent and in-segment late loss and binary restenosis rates are accordingly low and comparable to the paclitaxel-eluting stent. The dual therapy stent was shown to be safe and effective, as well as non-inferior to the paclitaxel-eluting stent," Dr. Haude said.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. SXC Health Solutions to Host Fiscal 2009 Fourth Quarter and Year End Results Conference Call
3. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
4. First blinded study of venous insufficiency prevalence in MS shows promising results
5. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
6. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
7. Kaiser Foundation Health Plan and Hospitals Report Fourth Quarter and Fiscal Year 2009 Financial Results
8. United American Healthcare Corporation Announces Fiscal 2010 Second Quarter Results
9. Fitness Trend Towards Online Personal Training Gets Real-World Weight Loss Results on FitOrbit.com
10. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
11. WebMD Announces Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology: